Imaratx.com

Imaratx.com has Server used 68.66.216.28 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2016-03-08 (5 years, 226 days) and hosted in Chicago United States, server ping response time 24 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Imaratx keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Imaratx
2 Imaratx stock

Hosting Provider

Website: Imaratx.com
Hostname: mi3-ss19.a2hosting.com
Country:
Region: IL
City: Chicago
Postal Code: 60607
Latitude: 41.874500274658
Longitude: -87.650299072266
Area Code: 312
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

Results For Websites Listing

Found 45 Websites with content related to this domain, It is result after search with search engine

Imara: Advancing New Sickle Cell Therapies

Imaratx.com   DA: 11 PA: 11 MOZ Rank: 22

Imara TX Application Manager

Imaratx.submittable.com   DA: 23 PA: 7 MOZ Rank: 31

  • Grantor Contact Information: If you have difficulty accessing the full announcement or need further assistance, please contact [email protected]imaratx.com or Jennifer Fields @ +1 617-206-2020

Imara Announces Pricing Of Public Offering

Ir.imaratx.com   DA: 14 PA: 50 MOZ Rank: 66

Imara Inc. LinkedIn

Linkedin.com   DA: 16 PA: 17 MOZ Rank: 36

  • is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies

سامانه اعتبارسنجی مرات اعتبارسنجی، رتبه بندی و گزارش اعتباری

User.imerat.ir   DA: 14 PA: 14 MOZ Rank: 32

  • سامانه اعتبارسنجی مرآت، ارائه دهنده خدمات اعتبارسنجی، رتبه‌بندی و گزارش اعتباری است
  • خدمات و گزارش رتبه بندی اعتباری، گزارش رتبه بندی اقتصادی و گزارش اعتبارسنجی به منظور مدیریت ریسک اعتباری برای بانک ها و سایر اشخاص

Imara To Present At Upcoming Investor Conferences

Ca.sports.yahoo.com   DA: 19 PA: 50 MOZ Rank: 74

  • [email protected]
  • Our goal is to create a safe and engaging place for users to connect over interests and passions
  • In order to improve our community experience, we are temporarily suspending article commenting.

IMRA Stock Forecast, Price & News (IMARA) MarketBeat

Marketbeat.com   DA: 18 PA: 20 MOZ Rank: 44

  • 2 brokerages have issued 1 year target prices for IMARA's shares
  • Their forecasts range from $12.00 to $42.00
  • On average, they anticipate IMARA's stock price to reach $27.00 in the next year
  • This suggests a possible upside of 480.6% from the stock's current price
  • View analysts' price targets for IMARA or view top-rated stocks among Wall

Imara To Present At Upcoming Investor Conferences

Globenewswire.com   DA: 21 PA: 50 MOZ Rank: 78

  • For more information, please visit www.imaratx.com
  • Media Contact: Marin Bergman Ten Bridge Communications 818-516-2746 [email protected]

Imara To Participate In Upcoming

Imaratx.gcs-web.com   DA: 19 PA: 50 MOZ Rank: 77

Imaratx.com 1 Year, 156 Days Left

Site-stats.org   DA: 14 PA: 13 MOZ Rank: 36

  • Imaratx.com Creation Date: 2016-03-08 | 1 year, 156 days left
  • Register domain GoDaddy.com, LLC store at supplier A2 Hosting, Inc

IMARA (NasdaqGS:IMRA)

Simplywall.st   DA: 13 PA: 50 MOZ Rank: 73

  • https://imaratx.com IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin
  • It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia.

Imara Presents Clinical Data On IMR

Imaratx.gcs-web.com   DA: 19 PA: 50 MOZ Rank: 80

  • IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types
  • For more information, please visit www.imaratx.com
  • Cautionary Note Regarding Forward-Looking Statements

Imara (IMR-687) – TIF

Thalassaemia.org.cy   DA: 19 PA: 45 MOZ Rank: 76

Update: 30 June 2021 Data presented at EHA2021 from the phase 2a clinical trial for the safety and efficacy of IMR-687 in 93 SCD patients showe

Imara Presents IMR-687 Phase 2a Open Label Extension Case

Globenewswire.com   DA: 21 PA: 50 MOZ Rank: 84

Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and

Working At Imara Glassdoor

Glassdoor.com   DA: 17 PA: 49 MOZ Rank: 80

  • Glassdoor gives you an inside look at what it's like to work at imara, including salaries, reviews, office photos, and more
  • This is the imara company profile.

Hematology-Focused Biotech Imara To IPO Soon The Motley Fool

Fool.com   DA: 12 PA: 50 MOZ Rank: 77

Follow @BiologyFool. Imara, which is developing a drug for sickle cell disease and beta thalassemia, has set the terms for its initial public offering (IPO), with shares expected to sell for $16

Imara To Participate In Upcoming Investor Conferences

Bakersfield.com   DA: 19 PA: 50 MOZ Rank: 85

  • For more information, please visit www.imaratx.com
  • Media Contact: Marin Bergman Ten Bridge Communications 818-516-2746 [email protected] Investor Contact: Michael …

Imara Announces Completion Of Patient Enrollment In Ardent

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 84

  • For more information, please visit www.imaratx.com
  • Cautionary Note Regarding Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as

Imara Stock Forecast: Down To 0.000001 USD

Walletinvestor.com   DA: 18 PA: 37 MOZ Rank: 73

  • If you want to learn more about Imara visit their website at imaratx.com
  • Imara Inc Stock Price Prediction, Stock Forecast for next months and years Below you will find the stock price predictions for 2021, 2022
  • Date Opening price Closing price Minimum price Maximum price Change; Imara Inc …

Imara Expands Management Team And

Businesswire.com   DA: 20 PA: 50 MOZ Rank: 89

  • Imara Company / Investors: Michael Gray 857-320-4636 [email protected]imaratx.com Release Summary Imara Inc
  • today announced the expansion of its …

Imara Inc. CipherBio

Cipherbio.com   DA: 17 PA: 33 MOZ Rank: 70

  • is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies
  • Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain.

Imara VentureRadar

Ventureradar.com   DA: 20 PA: 50 MOZ Rank: 91

  • is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin
  • Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day

Imara Announces Completion Of Patient Enrollment In Ardent

Biospace.com   DA: 16 PA: 50 MOZ Rank: 88

  • For more information, please visit www.imaratx.com
  • Cautionary Note Regarding Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The

Farah Natoli

Linkedin.com   DA: 16 PA: 24 MOZ Rank: 63

  • Issued April 26, 2016United States9320799
  • Patent# 9320711, Methods and Compositions for CNS Delivery of Heparan N-Sulfatase (26Apr, 2016) - Farah Natoli, …

Imara To Present At Upcoming Investor Conferences

Woodlandreport.com   DA: 18 PA: 50 MOZ Rank: 92

  • A live webcast of the presentations will be available under “Events and Presentations” in the Investors section of the company’s website at www.imaratx.com
  • is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic

Imara To Present At Upcoming Investor Conferences

Apnews.com   DA: 10 PA: 50 MOZ Rank: 85

  • A live webcast of the presentations will be available under “Events and Presentations” in the Investors section of the company’s website at www.imaratx.com
  • ADVERTISEMENT About Imara Imara Inc
  • is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare

Imara To Present At Upcoming Investor Conferences In

Biospace.com   DA: 16 PA: 50 MOZ Rank: 92

  • Attie will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021 at 11:00 a.m
  • A live webcast of the presentations will be available under "Events and Presentations" in the Investors section of the company's website at www.imaratx.com

Imara Inc Ordinary Shares (IMRA) Quote

Morningstar.com   DA: 19 PA: 23 MOZ Rank: 69

Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of

Imara To Present At Upcoming Investor Conferences IMRA

Stocktitan.net   DA: 18 PA: 50 MOZ Rank: 96

  • A live webcast of the presentations will be available under "Events and Presentations" in the Investors section of the company's website at www.imaratx.com
  • is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic

Imara To Participate In Upcoming Investor Conferences

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 96

  • Imara will participate in the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on September 22 and September 23, 2021
  • Rahul Ballal, Ph.D., President and Chief

Imara Opens Applications For The Second-Annual ‘Real

Apnews.com   DA: 10 PA: 50 MOZ Rank: 90

  • Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia
  • For more information, please visit www.imaratx.com.

Imara To Present At SVB Leerink 10th Annual Global

Stocktitan.net   DA: 18 PA: 50 MOZ Rank: 99

  • Do NOT follow this link! February 19, 2021 - 7:00 am
  • 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc
  • (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that Rahul Ballal, Ph.D., President and Chief Executive …

Imara To Present At Upcoming Investor Conferences

Morningstar.com   DA: 19 PA: 50 MOZ Rank: 18

  • For more information, please visit www.imaratx.com
  • Media Contact: Marin Bergman Ten Bridge Communications 818-516-2746 [email protected]

Imara Receives Orphan Drug Designation For IMR-687 For

Bloomberg.com   DA: 17 PA: 50 MOZ Rank: 100

  • For more information, please visit www.imaratx.com
  • Cautionary Note Regarding Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as

Imara Company Profile: Stock Performance & Earnings

Pitchbook.com   DA: 13 PA: 27 MOZ Rank: 74

  • Imara General Information Description
  • Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin.

Michael Medlock

Zoominfo.com   DA: 16 PA: 29 MOZ Rank: 80

  • is dedicated to developing novel therapeutics for patients with sickle cell disease and other hemoglobinopathies
  • Imara is currently developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with s

Recently Analyzed Sites